James E. Udelson MDChief, Division of Cardiology, Director, Nuclear Cardiology Laboratory, Tufts Medical Center, and Professor, Medicine and Radiology, Tufts University School of Medicine, Boston, Massachusetts
Dr. James Udelson is Chief of the Division of Cardiology as well as Director of Nuclear Cardiology at Tufts Medical Center. He is a Professor of Medicine and Radiology at Tufts University School of Medicine in Boston, and in 2012 received the Distinguished Faculty Award from the Medical School. Dr. Udelson’s research interests involve studying the effects of new therapeutic modalities in the setting of heart failure as well as chronic coronary artery disease, as well as studying the development of imaging modalities to assess those effects.
He was an Associate Editor for the American Heart Association’s cardiovascular journal Circulation from 2004 - 2016. In 2008, he was appointed as the initial Editor-in-Chief for the AHA’s then new journal Circulation: Heart Failure. In the ensuing 4 years, Circulation Heart Failure attained the highest impact factor of all subspecialty heart failure journals, and which also places it in the top tier of all cardiovascular journals. He is on the editorial board and has served as a Guest-Editor for the Journal of the American College of Cardiology and the Journal of Nuclear Cardiology.
Dr Udelson has served on the AHA/ACC/ASNC Radionuclide Imaging Guidelines writing Task Force, as well as numerous other national Guideline and Appropriate Use Criteria writing groups, including as a co-chair of the ACC/ACR Writing Committee for Appropriate Use Criteria to Assess Imaging Modalities to Evaluate Chest Pain in the Emergency Department. He is a chapter author for Braunwald’s Heart Disease textbook for the past 4 editions as well as for the 2017 edition.
Dr. Udelson is Past-President of the 5,000 member American Society of Nuclear Cardiology, and has served a 5 year term on the Board of Trustees of the 30,000 member American College of Cardiology (ACC). He has chaired the ACC’s Cardiovascular Imaging Committee, served on the ACC Publications Committee, and completed a term as Chair of the ACC Governance Committee. He has recently completed a term as a member of the Executive Council of the Heart Failure Society of America.
He has served as a member of the FDA Medical Imaging Drugs Advisory Panel, is an invited advisor to the FDA’s Division of Medical Imaging and Hematology Products, and has been invited as an ad hoc member of the FDA’s Cardiovascular and Renal Drugs Advisory Panel and the Peripheral and Central Nervous System Advisory Panel. He is a member of the Association of University Cardiologists and the Association of Professors of Cardiology. He has been the recipient of several NIH grants for studies of the use of cardiac imaging to better understand the physiology of left ventricular function and to favorably influence clinical decision making, He has directed and/or participated in numerous clinical trials on heart failure and cardiac imaging, focusing on the role of new therapies and how they affect remodeling, physiology, function, and outcomes.. Locally, he has been named many times by Boston magazines as one of Boston’s Best Doctors in cardiology.
Dr. Udelson is on the scientific advisory board and/or trial committees for GE Healthcare, Bayer, Medtrace, LivaNova, scPharma, Cardurion, Imbria, and Abiomed.
Recent Contributions to PracticeUpdate:
- Coronary 18F-Fluoride Uptake Identifies Progression of Coronary Artery Calcification
- 2020 Top Stories in Cardiology: The ISCHEMIA Trial and ISCHEMIA-CKD
- Automated Recognition of Regional Wall Motion Abnormalities Through Deep Neural Network Interpretation of Transthoracic Echocardiography
- Echo Findings in US Children With MIS-C and COVID-19
- Imaging of Clinically Unrecognized Myocardial Fibrosis in Patients With Suspected Coronary Artery Disease
- PET/CT Marker of Depression in Chronic Systolic HF
- Cardiac Manifestations of COVID-19 by Echocardiography
- Cardiac Involvement in Recovered COVID-19 Patients Identified by MRI
- Vericiguat in Patients With HFrEF
- ACC: New Data From the ISCHEMIA Trial on Revascularization vs Optimal Medical Therapy